This article examines whether the amendment to the Indian Patents Act, 1970 has taken advantage of the provisions available under the TRIPS agreement, and look at the exemption, exception and compulsory licensing provisions in pharmaceuticals.
To continue reading, become a subscriber.
Explore our attractive subscription offers.
Click here
